Dear Sir. Concerning your issue about the meaning of biomarkers in MRI brain tumor segmentation . Early biomarkers of tumor response to anti-angiogenic therapy are urgently needed to enable the rapid assessment and tailoring of drug therapies. MRI biomarkers are increasingly being used to assess the efficacy of tumor therapies. In particular, MRI methods for characterizing the tumor vascular structure, including the cerebral blood volume (CBV) , microvascular blood volume (MBV: vascular volume pertaining only to relatively small diameter vessels) , and vessel caliber index (VCI) have been developed and used to study changes in tumor vasculature with therapeutic treatment. In addition, the apparent diffusion coefficient (ADC), determined from diffusion-weighted images (DWI), and the transverse relaxation time (T2) have been used as biomarkers of tumor edema. Finally, I think the following below links may help you in your analysis:

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0017228

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933486/pdf/now036.pdf

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866963/pdf/MPHYA6-000043-002835_1.pdf

https://www.sciencedirect.com/science/article/pii/S2095882X16301347

Thanks

different biomarkers set is routinely utilized to assess, stratify and prognostication and judge the effecrt of ongoing chemotherapy and adjuvant therapy.

For example, intracerebral glioblastoma multiforme, a panel of biomarkers are used to quantify changes and prognostic value of diffusion MRI measurements obtained using mono-exponential, diffusion kurtosis imaging (DKI) and stretched exponential (SE) models prior and after chemoradiation in newly diagnosed glioblastoma .

Similarly for multiple myeloma multiple volumetric assess are used as biomarkers.